Abstract
A large number of human disorders are caused by defects in protein folding resulting from genetic mutations or adverse physiological conditions, and these are collectively referred to protein misfolding diseases. Such disorders imply dysfunction of a cellular process either as a result of a toxic gain of function due to protein aggregation, or loss of function due to protein instability, inefficient folding or defective trafficking. For a number of cases, drugs acting directly on the affected protein have been found to prevent misfolding and rescue function. This brief review will illustrate molecular mechanisms through which small molecules acting as folding correctors can prevent excessive protein buildup or recover faulty protein conformers, thus acting as effective therapeutic pharmacological chaperones. As background, the principles underlying the thermodynamics and kinetics of the protein folding reaction will be overviewed, as well as pathways leading to the formation of misfolding. The mechanism of action of small molecule correctors will then be discussed in light of these basic principles using illustrative examples referring to drugs that are effective over proteins involved in trafficking and folding diseases, amyloid aggregation disorders and metabolic deficiencies. An outlook on synergistic effects between different folding correctors and their combination with proteostasis regulators will also be addressed, as a relevant strategy towards the design of more effective therapies against protein folding diseases.
Keywords: Protein folding, protein aggregation, protein stability, amyloid, pharmacological chaperone, folding correctors, proteostasis, neurodegenerative diseases, metabolic diseases, lysosomal diseases, alzheimer’s disease, amyotrophic lateral sclerosis, familial amyotrophic polyneuropathy, loss of function, toxic gain of function, tafamidis, VX-809, isofagomine, migalastat, duvoglustat, tetrahydrobiopterin, riboflavin
Current Topics in Medicinal Chemistry
Title:Protein Misfolding in Disease and Small Molecule Therapies
Volume: 12 Issue: 22
Author(s): Claudio M. Gomes
Affiliation:
Keywords: Protein folding, protein aggregation, protein stability, amyloid, pharmacological chaperone, folding correctors, proteostasis, neurodegenerative diseases, metabolic diseases, lysosomal diseases, alzheimer’s disease, amyotrophic lateral sclerosis, familial amyotrophic polyneuropathy, loss of function, toxic gain of function, tafamidis, VX-809, isofagomine, migalastat, duvoglustat, tetrahydrobiopterin, riboflavin
Abstract: A large number of human disorders are caused by defects in protein folding resulting from genetic mutations or adverse physiological conditions, and these are collectively referred to protein misfolding diseases. Such disorders imply dysfunction of a cellular process either as a result of a toxic gain of function due to protein aggregation, or loss of function due to protein instability, inefficient folding or defective trafficking. For a number of cases, drugs acting directly on the affected protein have been found to prevent misfolding and rescue function. This brief review will illustrate molecular mechanisms through which small molecules acting as folding correctors can prevent excessive protein buildup or recover faulty protein conformers, thus acting as effective therapeutic pharmacological chaperones. As background, the principles underlying the thermodynamics and kinetics of the protein folding reaction will be overviewed, as well as pathways leading to the formation of misfolding. The mechanism of action of small molecule correctors will then be discussed in light of these basic principles using illustrative examples referring to drugs that are effective over proteins involved in trafficking and folding diseases, amyloid aggregation disorders and metabolic deficiencies. An outlook on synergistic effects between different folding correctors and their combination with proteostasis regulators will also be addressed, as a relevant strategy towards the design of more effective therapies against protein folding diseases.
Export Options
About this article
Cite this article as:
M. Gomes Claudio, Protein Misfolding in Disease and Small Molecule Therapies, Current Topics in Medicinal Chemistry 2012; 12 (22) . https://dx.doi.org/10.2174/1568026611212220002
DOI https://dx.doi.org/10.2174/1568026611212220002 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Structure of Ionotropic Glutamate Receptors
Current Medicinal Chemistry New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry Combating Protein Misfolding and Aggregation by Intracellular Antibodies
Current Molecular Medicine Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders
Current Molecular Medicine Acute Effects of Neutrophil-Derived Oxidative Stress on Pulmonary Microvasculature
Current Respiratory Medicine Reviews Monitoring Oxidative Stress Biomarkers in the Lipidome: Is There a Roadmap for “Human Inspection”?
Current Molecular Medicine Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Editorial: Protein Kinases and their Inhibitors
Current Enzyme Inhibition Nanomedicine
Current Nanoscience Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Peptide Agonists and Antagonists with Potential Application in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Inhibition of Ataxia Telangiectasia-p53-E2F-1 Pathway in Neurons as a Target for the Prevention of Neuronal Apoptosis
Current Drug Metabolism Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Patent Selections
Recent Patents on Food, Nutrition & Agriculture Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology